Histone deacetylase inhibition and the regulation of cell growth with particular reference to liver pathobiology

Journal of Cellular and Molecular Medicine

Volumn 13, Issue 9 B, 2009, Pages 2990-3005

  Joanna, Fraczek ^a   V G L A , van Grunsven Leo A ^a   Mathieu, Vinken ^a   Sarah, Snykers ^a   Sarah, Deleu ^a   Karin, Vanderkerken ^a   Tamara, Vanhaecke ^a   Vera, Rogiers ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Cell cycle; Hepatic stellate cells; Hepatocytes; Hepatoma; Histone deacetylase inhibitors; Histone deacetylases; Protein acetylation; Transdifferentiation

Indexed keywords

CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; HISTONE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; PROTEIN P53; TP53 PROTEIN, HUMAN;

ANIMAL; BIOLOGICAL MODEL; CELL PROLIFERATION; CYTOLOGY; FIBROSIS; HUMAN; INFLAMMATION; LIVER; LIVER CELL; LIVER CELL CARCINOMA; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; RETINOBLASTOMA; REVIEW;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FIBROSIS; HEPATOCYTES; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONES; HUMANS; INFLAMMATION; LIVER; MODELS, BIOLOGICAL; RETINOBLASTOMA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77649101042     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00831.x     Document Type: Review

References (155)

1. Sandman K, Reeve JN. Archaeal histones and the origin of the histone fold. Curr Opin Microbiol. 2006, 9:520-5.
2. Strahl BD, Allis CD. The language of covalent histone modifications. Nature. 2000, 403:41-5.
3. Luger K. Structure and dynamic behavior of nucleosomes. Curr Opin Genet Dev. 2003, 13:127-35.
4. Eberharter A, Becker PB. Histone acetylation: a switch between repressive and permissive chromatin. Second in review series on chromatin dynamics. EMBO Rep. 2002, 3:224-9.
5. de Ruijter AJ, van Gennip AH, Caron HN. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J. 2003, 370:737-49.
6. Hodawadekar SC, Marmorstein R. Chemistry of acetyl transfer by histone modifying enzymes: structure, mechanism and implications for effector design. Oncogene. 2007, 26:5528-40.
7. Legube G, Trouche D. Regulating histone acetyltransferases and deacetylases. EMBO Rep. 2003, 4:944-7.
8. Taunton J, Hassig CA, Schreiber SL. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science. 1996, 272:408-11.
9. Gregoretti IV, Lee YM, Goodson HV. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol. 2004, 338:17-31.
10. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006, 5:769-84.
11. Hildmann C, Riester D, Schwienhorst A. Histone deacetylases-an important class of cellular regulators with a variety of functions. Appl Microbiol Biotechnol. 2007, 75:487-97.
12. Sengupta N, Seto E. Regulation of histone deacetylase activities. J Cell Biochem. 2004, 93:57-67.
13. Yang XJ, Seto E. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene. 2007, 26:5310-8.
14. Denslow SA, Wade PA. The human Mi-2/NuRD complex and gene regulation. Oncogene. 2007, 26:5433-8.
15. Grozinger CM, Schreiber SL. Deacetylase enzymes: biological functions and the use of small-molecule inhibitors. Chem Biol. 2002, 9:3-16.
16. Gallinari P, Di Marco S, Jones P. HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics. Cell Res. 2007, 17:195-211.
17. Karagianni P, Wong J. HDAC3: taking the SMRT-N-CoRrect road to repression. Oncogene. 2007, 26:5439-49.
18. Fischle W, Dequiedt F, Hendzel MJ. Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol Cell. 2002, 9:45-57.
19. Fischle W, Kiermer V, Dequiedt F. The emerging role of class II histone deacetylases. Biochem Cell Biol. 2001, 79:337-48.
20. Margueron R, Trojer P, Reinberg D. The key to development: interpreting the histone code. Curr Opin Genet Dev. 2005, 15:163-76.
21. de la Cruz CC, Kirmizis A, Simon MD. The polycomb group protein SUZ12 regulates histone H3 lysine 9 methylation and HP1 alpha distribution. Chromosome Res. 2007, 15:299-314.
22. Santos-Rosa H, Caldas C. Chromatin modifier enzymes, the histone code and cancer. Eur J Cancer. 2005, 41:2381-402.
23. Glaser KB, Staver MJ, Waring JF. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther. 2003, 2:151-63.
24. Mitsiades CS, Mitsiades NS, McMullan CJ. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA. 2004, 101:540-5.
25. Van Lint C, Emiliani S, Verdin E. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr. 1996, 5:245-53.
26. Nusinzon I, Horvath CM. Histone deacetylases as transcriptional activators. Sci STKE 2005, 2005. Role reversal in inducible gene regulation, re11
27. Smith CL. A shifting paradigm: histone deacetylases and transcriptional activation. Bioessays. 2008, 30:15-24.
28. Glozak MA, Sengupta N, Zhang X. Acetylation and deacetylation of non-histone proteins. Gene. 2005, 363:15-23.
29. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006, 6:38-51.
30. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene. 2007, 26:5541-52.
31. Allis CD, Berger SL, Cote J. New nomenclature for chromatin-modifying enzymes. Cell. 2007, 131:633-6.
32. Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene. 2007, 26:5420-32.
33. Fraga MF, Ballestar E, Villar-Garea A. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet. 2005, 37:391-400.
34. Kramer OH, Gottlicher M, Heinzel T. Histone deacetylase as a therapeutic target. Trends Endocrinol Metab. 2001, 12:294-300.
35. Riggs MG, Whittaker RG, Neumann JR. n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells. Nature. 1977, 268:462-4.
36. Yoshida M, Kijima M, Akita M. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem. 1990, 265:17174-9.
37. Glaser KB. HDAC inhibitors: clinical update and mechanism-based potential. Biochem Pharmacol. 2007, 74:659-71.
38. Huang L. Targeting histone deacetylases for the treatment of cancer and inflammatory diseases. J Cell Physiol. 2006, 209:611-6.
39. Shankar S, Srivastava RK. Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis. Adv Exp Med Biol. 2008, 615:261-98.
40. Giacinti C, Giordano A. RB and cell cycle progression. Oncogene. 2006, 25:5220-7.
41. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell. 2002, 2:103-12.
42. Nevins JR. The Rb/E2F pathway and cancer. Hum Mol Genet. 2001, 10:699-703.
43. Luo RX, Postigo AA, Dean DC. Rb interacts with histone deacetylase to repress transcription. Cell. 1998, 92:463-73.
44. Gray SG, Iglesias AH, Lizcano F. Functional characterization of JMJD2A, a histone deacetylase- and retinoblastoma-binding protein. J Biol Chem. 2005, 280:28507-18.
45. Lai A, Kennedy BK, Barbie DA. RBP1 recruits the mSIN3-histone deacetylase complex to the pocket of retinoblastoma tumor suppressor family proteins found in limited discrete regions of the nucleus at growth arrest. Mol Cell Biol. 2001, 21:2918-32.
46. Shu KX, Li B, Wu LX. The p53 network: p53 and its downstream genes. Colloids Surf B Biointerfaces. 2007, 55:10-8.
47. Juven-Gershon T, Oren M. Mdm2: the ups and downs. Mol Med. 1999, 5:71-83.
48. Liu G, Chen X. Regulation of the p53 transcriptional activity. J Cell Biochem. 2006, 97:448-58.
49. Tokino T, Nakamura Y. The role of p53-target genes in human cancer. Crit Rev Oncol Hematol. 2000, 33:1-6.
50. Ito A, Kawaguchi Y, Lai CH. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J. 2002, 21:6236-45.
51. Luo J, Su F, Chen D. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature. 2000, 408:377-81.
52. Krummel KA, Lee CJ, Toledo F. The C-terminal lysines fine-tune P53 stress responses in a mouse model but are not required for stability control or transactivation. Proc Natl Acad Sci USA. 2005, 102:10188-93.
53. Feng L, Lin T, Uranishi H. Functional analysis of the roles of posttranslational modifications at the p53 C terminus in regulating p53 stability and activity. Mol Cell Biol. 2005, 25:5389-95.
54. Knights CD, Catania J, Di Giovanni S. Distinct p53 acetylation cassettes differentially influence gene-expression patterns and cell fate. J Cell Biol. 2006, 173:533-44.
55. Harms KL, Chen X. Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity. Cancer Res. 2007, 67:3145-52.
56. Murphy M, Ahn J, Walker KK. Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev. 1999, 13:2490-501.
57. Ho JS, Ma W, Mao DY. p53-Dependent transcriptional repression of c-myc is required for G1 cell cycle arrest. Mol Cell Biol. 2005, 25:7423-31.
58. Imbriano C, Gurtner A, Cocchiarella F. Direct p53 transcriptional repression: in vivo analysis of CCAAT-containing G2/M promoters. Mol Cell Biol. 2005, 25:3737-51.
59. el-Deiry WS. p21/p53, cellular growth control and genomic integrity. Curr Top Microbiol Immunol. 1998, 227:121-37.
60. el-Deiry WS, Tokino T, Velculescu VE. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993, 75:817-25.
61. Ocker M, Schneider-Stock R. Histone deacetylase inhibitors: signalling towards p21cip1/waf1. Int J Biochem Cell Biol. 2007, 39:1367-74.
62. Lagger G, O'Carroll D, Rembold M. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J. 2002, 21:2672-81.
63. Ma P, Schultz RM. Histone deacetylase 1 (HDAC1) regulates histone acetylation, development, and gene expression in preimplantation mouse embryos. Dev Biol. 2008, 319:110-20.
64. Wang AG, Kim SU, Lee SH. Histone deacetylase 1 contributes to cell cycle and apoptosis. Biol Pharm Bull. 2005, 28:1966-70.
65. Wang AG, Seo SB, Moon HB. Hepatic steatosis in transgenic mice overexpressing human histone deacetylase 1. Biochem Biophys Res Commun. 2005, 330:461-6.
66. Lagger G, Doetzlhofer A, Schuettengruber B. The tumor suppressor p53 and histone deacetylase 1 are antagonistic regulators of the cyclin-dependent kinase inhibitor p21/WAF1/CIP1 gene. Mol Cell Biol. 2003, 23:2669-79.
67. Huang W, Tan D, Wang X. Histone deacetylase 3 represses p15(INK4b) and p21(WAF1/cip1) transcription by interacting with Sp1. Biochem Biophys Res Commun. 2006, 339:165-71.
68. Wilson AJ, Byun DS, Nasser S. HDAC4 promotes growth of colon cancer cells via repression of p21. Mol Biol Cell. 2008, 19:4062-75.
69. Milutinovic S, Zhuang Q, Szyf M. Proliferating cell nuclear antigen associates with histone deacetylase activity, integrating DNA replication and chromatin modification. J Biol Chem. 2002, 277:20974-8.
70. Naryzhny SN, Lee H. The post-translational modifications of proliferating cell nuclear antigen: acetylation, not phosphorylation, plays an important role in the regulation of its function. J Biol Chem. 2004, 279:20194-9.
71. Elaut G, Rogiers V, Vanhaecke T. The pharmaceutical potential of histone deacetylase inhibitors. Curr Pharm Des. 2007, 13:2584-620.
72. Adcock IM, Ito K, Barnes PJ. Histone deacetylation: an important mechanism in inflammatory lung diseases. Copd. 2005, 2:445-55.
73. Barnes PJ, Adcock IM, Ito K. Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur Respir J. 2005, 25:552-63.
74. Blanchard F, Chipoy C. Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases. Drug Discov Today. 2005, 10:197-204.
75. Anne-Laurence B, Caroline R, Irina P. Chromatin acetylation status in the manifestation of neurodegenerative diseases: HDAC inhibitors as therapeutic tools. Subcell Biochem. 2007, 41:263-93.
76. Sadri-Vakili G, Cha JH. Histone deacetylase inhibitors: a novel therapeutic approach to Huntington's disease (complex mechanism of neuronal death). Curr Alzheimer Res. 2006, 3:403-8.
77. Saha RN, Pahan K. HATs and HDACs in neurodegeneration: a tale of disconcerted acetylation homeostasis. Cell Death Differ. 2006, 13:539-50.
78. Andrews KT, Tran TN, Lucke AJ. Potent antimalarial activity of histone deacetylase inhibitor analogues. Antimicrob Agents Chemother. 2008, 52:1454-61.
79. Demonte D, Quivy V, Colette Y. Administration of HDAC inhibitors to reactivate HIV-1 expression in latent cellular reservoirs: implications for the development of therapeutic strategies. Biochem Pharmacol. 2004, 68:1231-8.
80. Varier RA, Kundu TK. Chromatin modifications (acetylation/ deacetylation/ methylation) as new targets for HIV therapy. Curr Pharm Des. 2006, 12:1975-93.
81. Quivy V, De Walque S, Van Lint C. Chromatin-associated regulation of HIV-1 transcription: implications for the development of therapeutic strategies. Subcell Biochem. 2007, 41:371-96.
82. Vermeulen K, Berneman ZN, Van Bockstaele DR. Cell cycle and apoptosis. Cell Prolif. 2003, 36:165-75.
83. Marcos R, Monteiro RA, Rocha E. Design-based stereological estimation of hepatocyte number, by combining the smooth optical fractionator and immunocytochemistry with anti-carcinoembryonic antigen polyclonal antibodies. Liver Int. 2006, 26:116-24.
84. Elaut G, Henkens T, Papeleu P. Molecular mechanisms underlying the dedifferentiation process of isolated hepatocytes and their cultures. Curr Drug Metab. 2006, 7:629-60.
85. Zimmermann A. Regulation of liver regeneration. Nephrol Dial Transplant 2004, 19:iv6-10.
86. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005, 115:209-18.
87. Brenner DA. Signal transduction during liver regeneration. J Gastroenterol Hepatol 1998, 13:S93-5.
88. Taub R. Liver regeneration 4: transcriptional control of liver regeneration. FASEB J. 1996, 10:413-27.
89. Glaise D, Ilyin GP, Loyer P. Cell cycle gene regulation in reversibly differentiated new human hepatoma cell lines. Cell Growth Differ. 1998, 9:165-76.
90. Papeleu P, Loyer P, Vanhaecke T. Trichostatin A induces differential cell cycle arrests but does not induce apoptosis in primary cultures of mitogen-stimulated rat hepatocytes. J Hepatol. 2003, 39:374-82.
91. Papeleu P, Wullaert A, Elaut G. Inhibition of NF-kappaB activation by the histone deacetylase inhibitor 4-Me2N-BAVAH induces an early G1 cell cycle arrest in primary hepatocytes. Cell Prolif. 2007, 40:640-55.
92. Hoberg JE, Yeung F, Mayo MW. SMRT derepression by the IkappaB kinase alpha: a prerequisite to NF-kappaB transcription and survival. Mol Cell. 2004, 16:245-55.
93. Graham B, Gibson SB. The two faces of NFkappaB in cell survival responses. Cell Cycle. 2005, 4:1342-5.
94. Shetty S, Graham BA, Brown JG. Transcription factor NF-kappaB differentially regulates death receptor 5 expression involving histone deacetylase 1. Mol Cell Biol. 2005, 25:5404-16.
95. Perkins ND. Post-translational modifications regulating the activity and function of the nuclear factor kappa B pathway. Oncogene. 2006, 25:6717-30.
96. Hu J, Colburn NH. Histone deacetylase inhibition down-regulates cyclin D1 transcription by inhibiting nuclear factor-kappaB/p65 DNA binding. Mol Cancer Res. 2005, 3:100-9.
97. Larsen L, Tonnesen M, Ronn SG. Inhibition of histone deacetylases prevents cytokine-induced toxicity in beta cells. Diabetologia. 2007, 50:779-89.
98. Chiba T, Yokosuka O, Arai M. Identification of genes up-regulated by histone deacetylase inhibition with cDNA microarray and exploration of epigenetic alterations on hepatoma cells. J Hepatol. 2004, 41:436-45.
99. Boutillier AL, Trinh E, Loeffler JP. Selective E2F-dependent gene transcription is controlled by histone deacetylase activity during neuronal apoptosis. J Neurochem. 2003, 84:814-28.
100. Wang GL, Salisbury E, Shi X. HDAC1 cooperates with C/EBPalpha in the inhibition of liver proliferation in old mice. J Biol Chem. 2008, 283:26169-78.
101. Wang GL, Salisbury E, Shi X. HDAC1 promotes liver proliferation in young mice via interactions with C/EBPbeta. J Biol Chem. 2008, 283:26179-87.
102. Henkens T, Papeleu P, Elaut G. Trichostatin A, a critical factor in maintaining the functional differentiation of primary cultured rat hepatocytes. Toxicol Appl Pharmacol. 2007, 218:64-71.
103. Vinken M, Henkens T, Vanhaecke T. Trichostatin a enhances gap junctional intercellular communication in primary cultures of adult rat hepatocytes. Toxicol Sci. 2006, 91:484-92.
104. Fraczek J, Deleu S, Lukaszuk A. Screening of amide analogues of Trichostatin A in cultures of primary rat hepatocytes: search for potent and safe HDAC inhibitors. Invest New Drugs. 2008, 27:338-46.
105. Vanhaecke T, Henkens T, Kass GE. Effect of the histone deacetylase inhibitor trichostatin A on spontaneous apoptosis in various types of adult rat hepatocyte cultures. Biochem Pharmacol. 2004, 68:753-60.
106. Parkin DM, Bray F, Ferlay J. Global cancer statistics, 2002. CA Cancer J Clin. 2005, 55:74-108.
107. Schafer DF, Sorrell MF. Hepatocellular carcinoma. Lancet. 1999, 353:1253-7.
108. Lau WY, Lai EC. Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreat Dis Int. 2008, 7:237-57.
109. Xu XR, Huang J, Xu ZG. Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver. Proc Natl Acad Sci USA. 2001, 98:15089-94.
110. Chen X, Cheung ST, So S. Gene expression patterns in human liver cancers. Mol Biol Cell. 2002, 13:1929-39.
111. Fabregat I, Roncero C, Fernandez M. Survival and apoptosis: a dysregulated balance in liver cancer. Liver Int. 2007, 27:155-62.
112. Tannapfel A, Wittekind C. Genes involved in hepatocellular carcinoma: deregulation in cell cycling and apoptosis. Virchows Arch. 2002, 440:345-52.
113. Park BL, Kim YJ, Cheong HS. HDAC10 promoter polymorphism associated with development of HCC among chronic HBV patients. Biochem Biophys Res Commun. 2007, 363:776-81.
114. Yamamoto H, Fujimoto J, Okamoto E. Suppression of growth of hepatocellular carcinoma by sodium butyrate in vitro and in vivo. Int J Cancer. 1998, 76:897-902.
115. Herold C, Ganslmayer M, Ocker M. The histone-deacetylase inhibitor Trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells. J Hepatol. 2002, 36:233-40.
116. Svechnikova I, Gray SG, Kundrotiene J. Apoptosis and tumor remission in liver tumor xenografts by 4-phenylbutyrate. Int J Oncol. 2003, 22:579-88.
117. Yamashita Y, Shimada M, Harimoto N. Histone deacetylase inhibitor trichostatin A induces cell-cycle arrest/apoptosis and hepatocyte differentiation in human hepatoma cells. Int J Cancer. 2003, 103:572-6.
118. Armeanu S, Pathil A, Venturelli S. Apoptosis on hepatoma cells but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357. J Hepatol. 2005, 42:210-7.
119. Coradini D, Speranza A. Histone deacetylase inhibitors for treatment of hepatocellular carcinoma. Acta Pharmacol Sin. 2005, 26:1025-33.
120. Richon VM, Sandhoff TW, Rifkind RA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA. 2000, 97:10014-9.
121. Gui CY, Ngo L, Xu WS. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci USA. 2004, 101:1241-6.
122. Chiba T, Yokosuka O, Fukai K. Cell growth inhibition and gene expression induced by the histone deacetylase inhibitor, trichostatin A, on human hepatoma cells. Oncology. 2004, 66:481-91.
123. Zhao Y, Lu S, Wu L. Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1). Mol Cell Biol. 2006, 26:2782-90.
124. Wynn TA. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest. 2007, 117:524-9.
125. Guyot C, Lepreux S, Combe C. Hepatic fibrosis and cirrhosis: the (myo)fibroblastic cell subpopulations involved. Int J Biochem Cell Biol. 2006, 38:135-51.
126. Mann DA, Smart DE. Transcriptional regulation of hepatic stellate cell activation. Gut. 2002, 50:891-6.
127. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev. 2008, 88:125-72.
128. Forbes SJ, Russo FP, Rey V. A significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis. Gastroenterology. 2004, 126:955-63.
129. Iredale JP. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest. 2007, 117:539-48.
130. Funakoshi F, Masaki T, Kita Y. Proliferative capability of hepatocytes and expression of G1-related cell cycle molecules in the development of liver cirrhosis in rats. Int J Mol Med. 2004, 13:779-87.
131. Gressner AM, Lahme B, Mannherz HG. TGF-beta-mediated hepatocellular apoptosis by rat and human hepatoma cells and primary rat hepatocytes. J Hepatol. 1997, 26:1079-92.
132. Muddu AK, Guha IN, Elsharkawy AM. Resolving fibrosis in the diseased liver: translating the scientific promise to the clinic. Int J Biochem Cell Biol. 2007, 39:695-714.
133. Okuda H. Hepatocellular carcinoma development in cirrhosis. Best Pract Res Clin Gastroenterol. 2007, 21:161-73.
134. Niki T, Rombouts K, De Bleser P. A histone deacetylase inhibitor, trichostatin A, suppresses myofibroblastic differentiation of rat hepatic stellate cells in primary culture. Hepatology. 1999, 29:858-67.
135. Rombouts K, Niki T, Wielant A. Trichostatin A, lead compound for development of antifibrogenic drugs. Acta Gastroenterol Belg. 2001, 64:239-46.
136. Rombouts K, Knittel T, Machesky L. Actin filament formation, reorganization and migration are impaired in hepatic stellate cells under influence of trichostatin A, a histone deacetylase inhibitor. J Hepatol. 2002, 37:788-96.
137. Derk CT, Jimenez SA. Systemic sclerosis: current views of its pathogenesis. Autoimmun Rev. 2003, 2:181-91.
138. Ghosh AK, Mori Y, Dowling E. Trichostatin A blocks TGF-beta-induced collagen gene expression in skin fibroblasts: involvement of Sp1. Biochem Biophys Res Commun. 2007, 354:420-6.
139. Rishikof DC, Ricupero DA, Liu H. Phenylbutyrate decreases type I collagen production in human lung fibroblasts. J Cell Biochem. 2004, 91:740-8.
140. Rombouts K, Niki T, Greenwel P. Trichostatin A, a histone deacetylase inhibitor, suppresses collagen synthesis and prevents TGF-beta(1)-induced fibrogenesis in skin fibroblasts. Exp Cell Res. 2002, 278:184-97.
141. Huber LC, Distler JH, Moritz F. Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycin-induced skin fibrosis. Arthritis Rheum. 2007, 56:2755-64.
142. Young DA, Billingham O, Sampieri CL. Differential effects of histone deacetylase inhibitors on phorbol ester- and TGF-beta1 induced murine tissue inhibitor of metalloproteinases-1 gene expression. FEBS J. 2005, 272:1912-26.
143. Iredale JP, Benyon RC, Arthur MJ. Tissue inhibitor of metalloproteinase-1 messenger RNA expression is enhanced relative to interstitial collagenase messenger RNA in experimental liver injury and fibrosis. Hepatology. 1996, 24:176-84.
144. Murphy FR, Issa R, Zhou X. Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis. J Biol Chem. 2002, 277:11069-76.
145. Verrecchia F, Mauviel A. Transforming growth factor-beta and fibrosis. World J Gastroenterol. 2007, 13:3056-62.
146. Itoh S, ten Dijke P. Negative regulation of TGF-beta receptor/Smad signal transduction. Curr Opin Cell Biol. 2007, 19:176-84.
147. Massague J, Seoane J, Wotton D. Smad transcription factors. Genes Dev. 2005, 19:2783-810.
148. Massague J, Wotton D. Transcriptional control by the TGF-beta/Smad signaling system. EMBO J. 2000, 19:1745-54.
149. van Grunsven LA, Verstappen G, Huylebroeck D. Smads and chromatin modulation. Cytokine Growth Factor Rev. 2005, 16:495-512.
150. Izutsu K, Kurokawa M, Imai Y. The corepressor CtBP interacts with Evi-1 to repress transforming growth factor beta signaling. Blood. 2001, 97:2815-22.
151. Long J, Matsuura I, He D. Repression of Smad transcriptional activity by PIASy, an inhibitor of activated STAT. Proc Natl Acad Sci USA. 2003, 100:9791-6.
152. Wotton D, Knoepfler PS, Laherty CD. The Smad transcriptional corepressor TGIF recruits mSin3. Cell Growth Differ. 2001, 12:457-63.
153. Simonsson M, Heldin CH, Ericsson J. The balance between acetylation and deacetylation controls Smad7 stability. J Biol Chem. 2005, 280:21797-803.
154. Poncelet AC, Schnaper HW. Sp1 and Smad proteins cooperate to mediate transforming growth factor-beta 1-induced alpha 2(I) collagen expression in human glomerular mesangial cells. J Biol Chem. 2001, 276:6983-92.
155. Glenisson W, Castronovo V, Waltregny D. Histone deacetylase 4 is required for TGFbeta1-induced myofibroblastic differentiation. Biochim Biophys Acta. 2007, 1773:1572-82.